313 related articles for article (PubMed ID: 29490757)
1. Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles.
Zhu X; Guo X; Liu D; Gong Y; Sun J; Dong C
J Biomed Nanotechnol; 2017 Dec; 13(12):1694-1705. PubMed ID: 29490757
[TBL] [Abstract][Full Text] [Related]
2. Enhanced rapamycin delivery to hemangiomas by lipid polymer nanoparticles coupled with anti-VEGFR antibody.
Li H; Teng Y; Xu X; Liu J
Int J Mol Med; 2018 Jun; 41(6):3586-3596. PubMed ID: 29512710
[TBL] [Abstract][Full Text] [Related]
3. Significant inhibition of infantile hemangioma growth by sustained delivery of urea from liposomes-in-microspheres.
Zhu X; Guo X; Liu D; Gong Y; Sun J; Dong C
Oncol Rep; 2018 Jan; 39(1):109-118. PubMed ID: 29192323
[TBL] [Abstract][Full Text] [Related]
4. Continuous delivery of propranolol from liposomes-in-microspheres significantly inhibits infantile hemangioma growth.
Guo X; Zhu X; Liu D; Gong Y; Sun J; Dong C
Int J Nanomedicine; 2017; 12():6923-6936. PubMed ID: 29075111
[TBL] [Abstract][Full Text] [Related]
5. The sustained and targeted treatment of hemangiomas by propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres.
Guo X; Dong C; Liu Q; Zhu X; Zuo S; Zhang H
Biomed Pharmacother; 2019 Jun; 114():108823. PubMed ID: 30965238
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hemangioma growth using polymer-lipid hybrid nanoparticles for delivery of rapamycin.
Li H; Teng Y; Sun J; Liu J
Biomed Pharmacother; 2017 Nov; 95():875-884. PubMed ID: 28903183
[TBL] [Abstract][Full Text] [Related]
7. PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma.
Guo X; Zhu X; Gao J; Liu D; Dong C; Jin X
Nanomedicine (Lond); 2017 Nov; 12(21):2611-2624. PubMed ID: 28960167
[TBL] [Abstract][Full Text] [Related]
8. Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner.
Li P; Guo Z; Gao Y; Pan W
Oncol Rep; 2015 Jun; 33(6):3099-107. PubMed ID: 25872592
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of propranolol therapy for infantile hemangiomas based on a mesoporous silica nanoplatform through mediating autophagy dysfunction.
Wu H; Wang X; Liang H; Zheng J; Huang S; Zhang D
Acta Biomater; 2020 Apr; 107():272-285. PubMed ID: 32145394
[TBL] [Abstract][Full Text] [Related]
10. Propranolol-Loaded Mesoporous Silica Nanoparticles for Treatment of Infantile Hemangiomas.
Wu H; Wang X; Zheng J; Zhang L; Li X; Yuan WE; Liu X
Adv Healthc Mater; 2019 May; 8(9):e1801261. PubMed ID: 30838782
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?
Babiak-Choroszczak L; Giżewska-Kacprzak K; Gawrych E; Fischer K; Walecka A; Puchalska-Niedbał L; Rajewska-Majchrzak J; Bagłaj M
Adv Clin Exp Med; 2018 May; 27(5):703-710. PubMed ID: 29790692
[TBL] [Abstract][Full Text] [Related]
12. Propranolol for infantile hemangiomas.
Bagazgoitia L; Torrelo A; Gutiérrez JC; Hernández-Martín A; Luna P; Gutiérrez M; Baño A; Tamariz A; Larralde M; Alvarez R; Pardo N; Baselga E
Pediatr Dermatol; 2011; 28(2):108-14. PubMed ID: 21385205
[TBL] [Abstract][Full Text] [Related]
13. Study on the Mechanism of Targeted Poly(lactic-coglycolic acid) Nano-Delivery Carriers in the Treatment of Hemangiomas.
Liao S; Wu J; Li Z; Cheng G; Lu B; Liu G; Li X; Lu W
J Nanosci Nanotechnol; 2021 Feb; 21(2):1236-1243. PubMed ID: 33183467
[TBL] [Abstract][Full Text] [Related]
14. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.
Chim H; Armijo BS; Miller E; Gliniak C; Serret MA; Gosain AK
Ann Surg; 2012 Jul; 256(1):146-56. PubMed ID: 22580939
[TBL] [Abstract][Full Text] [Related]
15. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
Pan WK; Li P; Guo ZT; Huang Q; Gao Y
Pediatr Blood Cancer; 2015 Aug; 62(8):1414-20. PubMed ID: 25728347
[TBL] [Abstract][Full Text] [Related]
16. Propranolol for Treatment of Genital Infantile Hemangioma.
Tran C; Tamburro J; Rhee A; Golden A
J Urol; 2016 Mar; 195(3):731-7. PubMed ID: 26400030
[TBL] [Abstract][Full Text] [Related]
17. Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy.
Chen XD; Ma G; Huang JL; Chen H; Jin YB; Ye XX; Hu XJ; Lin XX
Pediatr Dermatol; 2013; 30(5):549-53. PubMed ID: 23909679
[TBL] [Abstract][Full Text] [Related]
18. The use of propranolol for complicated infantile hemangiomas.
Vercellino N; Romanini MV; Pelegrini M; Rimini A; Occella C; Dalmonte P
Int J Dermatol; 2013 Sep; 52(9):1140-6. PubMed ID: 23829783
[TBL] [Abstract][Full Text] [Related]
19. Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use.
Laken PA
Adv Neonatal Care; 2016 Apr; 16(2):135-42. PubMed ID: 26945282
[TBL] [Abstract][Full Text] [Related]
20. Preparation and cellular targeting study of VEGF-conjugated PLGA nanoparticles.
Shi Y; Zhou M; Zhang J; Lu W
J Microencapsul; 2015; 32(7):699-704. PubMed ID: 26004370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
